logo-loader

Full interview: Nuvo Pharmaceuticals subsidiary announces Takeda’s Cabpirin approved in Japan

Published: 15:50 01 Apr 2020 EDT

Nuvo Pharmaceuticals (TSE: NRI- OTCQX: NRIFF) President and CEO Jesse Ledger joined Steve Darling from Proactive in Vancouver to discuss the company’s Nuvo Ireland announcing  Takeda Pharmaceutical has given notice  Japan's Ministry of Health, Labor and Welfare have approved Cabpirin combination tablets.

Ledger discusses what this means for the company and its revenue going forward. Ledger also told Proactive how the company is dealing with COVID-19 right now and in the future.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 24 minutes ago